Trial to Assess the Effects of an Antimicrobial Mouthwash on the Esophageal Microbiome

• Status: Completed
• Trial end date: 2017-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a randomized, open-label pilot study to assess whether treatment with chlorhexidine mouthwash can alter the esophageal and gastric cardia microbiome

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Columbia University
• Treatments: Anti-Infective Agents; Chlorhexidine; Chlorhexidine gluconate

Criteria

Inclusion Criteria:

• Age >18

• Scheduled for upper endoscopy for clinical indications

• No allergy or other contraindication to chlorhexidine

Exclusion Criteria:

• Use of proton pump inhibitors or H2 receptor antagonists within 1 month of enrollment. Acid suppressant medications raise the gastric pH and can dramatically alter the gastric and esophageal microbiome.

• History of upper gastrointestinal cancer

• History of histologically proven Barrett's esophagus

• History of antireflux or bariatric surgery, or other gastric or esophageal surgery

• Use of antimicrobial mouthwash within 1 month of enrollment

• Use of antibiotics or immunosuppressant medications within 3 months of enrollment

• Use of steroid inhalers or nasal sprays within 1 month of enrollment

• HIV or other immunosuppressed states or conditions (e.g. active malignancy)

• Pregnant or breast feeding

• Inability to give informed consent